Witnessing the stock’s movement on the chart, on Wednesday, Arcus Biosciences Inc (NYSE: RCUS) had a quiet start as it plunged -6.33% to $14.65, before settling in for the price of $15.64 at the close. Taking a more long-term approach, RCUS posted a 52-week range of $12.95-$25.47.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that the giant of the Healthcare sector posted annual sales growth of 164.80% over the last 5 years. Meanwhile, its Annual Earning per share during the time was -23.70%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 23.22%. This publicly-traded company’s shares outstanding now amounts to $75.50 million, simultaneously with a float of $48.50 million. The organization now has a market capitalization sitting at $1.34 billion. At the time of writing, stock’s 50-day Moving Average stood at $15.28, while the 200-day Moving Average is $16.23.
Arcus Biosciences Inc (RCUS) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Arcus Biosciences Inc’s current insider ownership accounts for 46.96%, in contrast to 55.69% institutional ownership. According to the most recent insider trade that took place on Mar 27 ’24, this organization’s Chief Operating Officer sold 11,551 shares at the rate of 17.55, making the entire transaction reach 202,720 in total value, affecting insider ownership by 215,253. Preceding that transaction, on Mar 18 ’24, Company’s Chief Operating Officer sold 13,449 for 17.92, making the whole transaction’s value amount to 240,941. This particular insider is now the holder of 226,804 in total.
Arcus Biosciences Inc (RCUS) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.16 per share during the current fiscal year.
Arcus Biosciences Inc’s EPS increase for this current 12-month fiscal period is 23.22% and is forecasted to reach -4.74 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 7.80% through the next 5 years, which can be compared against the -23.70% growth it accomplished over the previous five years trading on the market.
Arcus Biosciences Inc (NYSE: RCUS) Trading Performance Indicators
Let’s observe the current performance indicators for Arcus Biosciences Inc (RCUS). It’s Quick Ratio in the last reported quarter now stands at 5.14. The Stock has managed to achieve an average true range (ATR) of 1.00. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 5.42.
In the same vein, RCUS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.10, a figure that is expected to reach -1.02 in the next quarter, and analysts are predicting that it will be -4.74 at the market close of one year from today.
Technical Analysis of Arcus Biosciences Inc (RCUS)
Going through the that latest performance of [Arcus Biosciences Inc, RCUS]. Its last 5-days volume of 0.73 million was inferior to the volume of 0.75 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 56.49% While, its Average True Range was 1.06.
Raw Stochastic average of Arcus Biosciences Inc (RCUS) in the period of the previous 100 days is set at 20.21%, which indicates a major fall in contrast to 33.43% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 90.46% that was higher than 56.30% volatility it exhibited in the past 100-days period.
